ClinicalTrials.gg
RecruitingNCT06350500Updated Feb 17, 2026

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

An interventional study of Patient Navigation and Questionnaire in Breast Carcinoma and Breast Ductal Carcinoma in Situ, sponsored by Roswell Park Cancer Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Primary conditionCarcinoma, Intraductal, NoninfiltratingRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Intraductal, Noninfiltrating
Why
  1. The study's listed conditions name Carcinoma, Intraductal, Noninfiltrating, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Roswell Park Cancer Institute · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Planned enrollment
45th of 171
126 · median 51
Started
2024
with 7 others
No phase
65 of 210
11 open now
Primary completion
2028-03
later than 38 of 50 live
Registered
197th of 210
by date

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 45th largest by planned enrollment of the 171 interventional ones that give a count, is one of 8 that started in 2024, is one of 65 with no phase, reaches primary completion later than 38 of the 50 other live ones, and was the 197th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

This clinical trial evaluates a patient navigation program for addressing disparities in breast cancer care. The navigation program is designed to help improve patient knowledge about clinical and supportive care services, navigate to existing services, help manage barriers to care, and enhance patient skills related to management of cancer treatment. Offering a patient navigation program may increase health equity and improve social needs and quality of life over time for newly diagnosed breast cancer patients.

Read the detailed description

PRIMARY OBJECTIVE:

I. Implement a patient navigation program in the Roswell Park Breast Clinic focused on underserved women with a first cancer diagnosis of breast cancer or ductal carcinoma in situ (DCIS) (n=126).

SECONDARY OBJECTIVE:

I. Systematically address barriers to care by connecting women with multiple barriers of care with a first diagnosis of breast cancer or DCIS to supportive services and culturally appropriate resources.

03

Conditions studied

  • Breast Carcinoma
  • Breast Ductal Carcinoma in Situ

Browse trials for

04

In context

Carcinoma, Intraductal, Noninfiltrating Reclassified

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

This study's planned enrollment of 126 is above the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

Roswell Park Cancer Institute is the lead sponsor of 419 studies on the registry; 65 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 21 (55%) have results posted.

Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age
  • Have a confirmed diagnosis of breast cancer or Ductal Carcinoma In Situ (DCIS)
  • Currently identify their gender as woman or female
  • Was assigned female sex at birth (AFAB)

    - Participant is experiencing ≥1 barrier to care as determined by the social needs screening tool

  • Participant must understand the nature of this study and verbally consent to participate prior to receiving any study related intervention

Exclusion criteria

Exclusion Criteria:

  • Participants who are not suspected of or diagnosed with breast cancer or Ductal Carcinoma in Situ (DCIS)
  • Participants who have had a previous diagnosis of any cancer
  • Participants who were assigned male sex or intersex at birth
  • Unwilling or unable to follow protocol requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Health Services Research (Patient Navigation)

    Patients receive patient navigation services from a patient navigator as needed to improve knowledge about clinical and supportive care services, navigate to existing services, help manage barriers to care, and enhance skills related to management of cancer treatment

    Behavioral: Patient Navigation · Other: Questionnaire

Interventions

  • BehavioralPatient Navigation

    Receive patient navigation

  • OtherQuestionnaire

    Ancillary studies

07

What researchers measure

Primary outcomes

  1. Enrollment rate

    Enrollment rate Will be defined as the number of patients enrolled divided by the number of patients approached. The enrollment rate will be estimated with a 90% credible region obtained by Jeffrey's prior method.

    Time frame: Up to 2 years

  2. Reasons for refusal

    Reported reasons of refusal will be summarized using frequencies and relative frequencies

    Time frame: Up to 2 years

  3. Retention Rate

    The number of patients that complete patient navigation divided by the number of patients enrolled

    Time frame: Up to 2 years

  4. Reasons for discontinuation

    Will be summarized using frequencies and relative frequencies

    Time frame: Up to 2 years

Secondary outcomes

  1. European Organization for Research and Treatment of Cancer Quality of Life Scale (EORTC QLQ-C30)

    the quality of life in breast cancer patients. Score averaged, transformed to 0-100 scale, higher score indicates better quality of life

    Time frame: Up to 2 years

  2. Social Determinates of health

    An 11 question survey . A score of 11 or more when the numerical values for answers to questions 7-10 are added shows that the person might not be safe.

    Time frame: Up to 2 years

  3. Barriers to care

    Patient navigators will meet with participants to discuss barriers to care. Results will be summarized

    Time frame: Up to 2 years

  4. Use of supportive services

    Will be summarized using frequencies and relative frequencies

    Time frame: Up to 2 years

  5. Patient Satisfaction survey

    Will be summarized (by time as appropriate) using frequencies and relative frequencies

    Time frame: up to 2 years

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Mar 2028, 39 months after the start.

Of 44 non-industry interventional studies with no phase under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 148. This study's planned 39 months is below that.

Counting every sponsor, half of 47 studies reached it within 69 months; a quarter within 30 and three quarters within 134.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 5, 2024
StartActual
Dec 15, 2024
Primary completionEst.
Mar 15, 2028
CompletionEst.
Mar 15, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350500
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Dec 15, 2024
Primary completion
Mar 15, 2028 (estimated)
Completion
Mar 15, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Kathryn Glaser
Contact
Kathryn.Glaser@roswellpark.org
716-845-7637
Kathryn Glaser
principal investigator · Roswell Park Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion